Travere Therapeutics (TVTX) Short term Debt (2018 - 2025)
Travere Therapeutics' (TVTX) quarterly Short term Debt came in at $68.8 million in Q2 2025, little changed on a QoQ basis from $68.8 million in Q1 2025.
Travere Therapeutics (TVTX) Short term Debt (2018 - 2025) Analysis & Trends
Travere Therapeutics (TVTX) has 8 years of Short term Debt data on file, last reported at $68.8 million in Q2 2025.
- Quarterly Short term Debt changed N/A year-over-year to $68.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $68.8 million (changed N/A YoY) and the FY2024 annual result came in at $68.7 million, changed N/A from the prior year.
- Short term Debt was little changed at $68.8 million in Q2 2025, from $68.8 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $68.8 million in Q2 2025 to a low of $6.9 million in Q1 2023.
- A 5-year average of $29.6 million and a median of $7.4 million in 2021 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2021 — Short term Debt slumped 57.47% — and 2022, when it dropped 5.41%.
- Tracing TVTX's Short term Debt over 5 years: stood at $7.4 million in 2021, then retreated by 5.41% to $7.0 million in 2022, then retreated by 1.43% to $6.9 million in 2023, then surged by 895.33% to $68.7 million in 2024, then rose by 0.23% to $68.8 million in 2025.
- The last three Short term Debt figures came in at $68.8 million (Q2 2025), $68.8 million (Q1 2025), and $68.7 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 68.84 Mn |
| Mar 31, 2025 | 68.76 Mn |
| Dec 31, 2024 | 68.68 Mn |
| Sep 30, 2024 | 68.60 Mn |
| Jun 30, 2023 | 6.90 Mn |
| Mar 31, 2023 | 6.90 Mn |
| Dec 31, 2022 | 7.00 Mn |
| Sep 30, 2022 | 7.30 Mn |
| Jun 30, 2022 | 7.30 Mn |
| Mar 31, 2022 | 7.50 Mn |
| Dec 31, 2021 | 7.40 Mn |
| Dec 31, 2020 | 17.40 Mn |
| Mar 31, 2019 | 22.54 Mn |
| Dec 31, 2018 | 22.46 Mn |
| Sep 30, 2018 | 22.38 Mn |
| Jun 30, 2018 | 45.40 Mn |